---
title: "Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272634618.md"
description: "Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial"
datetime: "2026-01-15T03:00:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272634618.md)
  - [en](https://longbridge.com/en/news/272634618.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272634618.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/272634618.md) | [繁體中文](https://longbridge.com/zh-HK/news/272634618.md)


# Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial



### Related Stocks

- [HUADONG MEDICINE (000963.CN)](https://longbridge.com/en/quote/000963.CN.md)

## Related News & Research

- [Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial](https://longbridge.com/en/news/274912733.md)
- [Huadong Medicine's Two Drugs Placed in China's Insurance Drug List](https://longbridge.com/en/news/268897142.md)
- [Nxera Submits South Korea Filing for Insomnia Drug Daridorexant](https://longbridge.com/en/news/277751126.md)
- [Antengene Signs Global License Deal With UCB for Autoimmune Drug Candidate](https://longbridge.com/en/news/277705757.md)
- [Pharmaceutical Glass Packaging Market Forecast 2026-2036: Market to Reach USD 14.2 Billion by 2036 at 5.1% CAGR](https://longbridge.com/en/news/277455697.md)